

**AMENDMENTS TO THE CLAIMS**

The listing of the claims replaces all prior versions and listings of the claims for this application.

Within this listing of the claims, claims 30-33, 35, 36, and 40-44 are newly canceled.

1. **(previously presented)** A method for treating a patient suffering from or predisposed to developing interstitial lung disease (ILD), comprising administering to the patient a pharmaceutical formulation that comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations of any of the foregoing.
2. **(original)** The method of claim 1, wherein the active agent is *cis*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.
3. **(original)** The method of claim 2, wherein the active agent is *cis*-resveratrol.
4. **(original)** The method of claim 2, wherein the active agent is a conjugate of *cis*-resveratrol and a mono- or di-saccharide.
5. **(original)** The method of claim 4, wherein the active agent is *cis*-resveratrol glucoside.
6. **(original)** The method of claim 1, wherein the active agent is *trans*-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.
7. **(original)** The method of claim 6, wherein the active agent is *trans*-resveratrol.
8. **(original)** The method of claim 6, wherein the active agent is a conjugate of *trans*-resveratrol and a mono- or di-saccharide.
9. **(original)** The method of claim 8, wherein the active agent is *trans*-resveratrol glucoside.
10. **(original)** The method of claim 1, wherein the active agent comprises a mixture of *cis*-resveratrol and *trans*-resveratrol.